 |
160 Products |  |
813 Diseases | | 160 Products |
|
1618 Trials |  |
78436 News |  |
| «12...878879880881882883884885886887888...910911» |
- ||| Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Trial completion: European Union Registry in Paediatric Chronic Kidney Disease Patients Looking at Safety and Usage Patterns of Darbepoetin Alfa (clinicaltrials.gov) - Jan 13, 2014
P=N/A, N=321, Completed, Sponsor: Amgen
Active, not recruiting --> Completed
- Actimmune (interferon gamma-1 b) / Clinigen, Amgen
New P2a trial: A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients (clinicaltrials.gov) - Jan 12, 2014
P2a, N=10, Recruiting, Sponsor: Azienda Policlinico Umberto I
- Kepivance (palifermin) / SOBI, Amgen
New P1/2 trial: Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis (clinicaltrials.gov) - Jan 12, 2014
P1/2, N=5, Recruiting, Sponsor: Brett King
- Kepivance (palifermin) / SOBI, Amgen
Enrollment open: Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis (clinicaltrials.gov) - Jan 12, 2014
P1/2, N=5, Recruiting, Sponsor: Brett King
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Vectibix (panitumumab) / Amgen
Enrollment closed: ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 12, 2014
P3, N=1010, Active, not recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || AMG 811 / Amgen
Enrollment closed: Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis (clinicaltrials.gov) - Jan 12, 2014
P1, N=56, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Prolia (denosumab) / Amgen
Trial completion: Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium (clinicaltrials.gov) - Jan 12, 2014
P2, N=33, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| ganitumab (AMG 479) / Takeda, ImmunityBio
Trial completion: Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab (clinicaltrials.gov) - Jan 12, 2014
P2, N=76, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Enbrel (etanercept) / Pfizer, Amgen
Enrollment change: AS@WORK: Work Productivity in Active Ankylosing Spondylitis (AS) Patients Treated With Enbrel. (clinicaltrials.gov) - Jan 9, 2014
P4, N=80, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed N=120 --> 80
- | Enrollment closed, Metastases: Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma (clinicaltrials.gov) - Jan 9, 2014
P2, N=20, Active, not recruiting, Sponsor: Stanford University
N=120 --> 80 Recruiting --> Active, not recruiting
- |||| Extimia (empegfilgrastim biosimilar) / Biocad
Trial completion: Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer (clinicaltrials.gov) - Jan 9, 2014
P2, N=60, Completed, Sponsor: Biocad
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: AS@WORK: Work Productivity in Active Ankylosing Spondylitis (AS) Patients Treated With Enbrel. (clinicaltrials.gov) - Jan 9, 2014
P4, N=80, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- prezalumab (AMG 557) / Amgen, AstraZeneca
Trial termination: Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus (clinicaltrials.gov) - Jan 8, 2014
P1, N=1, Terminated, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Terminated; slow enrollment
- prezalumab (AMG 557) / Amgen, AstraZeneca
Enrollment change: Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus (clinicaltrials.gov) - Jan 8, 2014
P1, N=1, Terminated, Sponsor: Amgen
Recruiting --> Terminated; slow enrollment N=32 --> 1
- |||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: Denosumab China Phase III Study (clinicaltrials.gov) - Jan 8, 2014
P3, N=444, Recruiting, Sponsor: GlaxoSmithKline
N=32 --> 1 Not yet recruiting --> Recruiting
- |||| abrilumab (AMG 181) / Amgen, AstraZeneca
Enrollment open: Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease (clinicaltrials.gov) - Jan 8, 2014
P2, N=252, Recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Suspended --> Recruiting
- ||||||| Repatha (evolocumab) / Amgen, Astellas
Trial completion: Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study (clinicaltrials.gov) - Jan 8, 2014
P3, N=901, Completed, Sponsor: Amgen
Suspended --> Recruiting Active, not recruiting --> Completed
- pevonedistat (MLN4924) / Takeda, Rituxan (rituximab) / Roche
Biomarker, Trial withdrawal: MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma (clinicaltrials.gov) - Jan 7, 2014
P1/2, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Trial withdrawal: Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov) - Jan 7, 2014
P2, N=0, Withdrawn, Sponsor: Case Comprehensive Cancer Center
Not yet recruiting --> Withdrawn Active, not recruiting --> Withdrawn
- pevonedistat (MLN4924) / Takeda, Rituxan (rituximab) / Roche
Biomarker, Enrollment change: MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma (clinicaltrials.gov) - Jan 7, 2014
P1/2, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Withdrawn N=56 --> 0
- abrilumab (AMG 181) / Amgen, AstraZeneca
Enrollment change: Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181. (clinicaltrials.gov) - Jan 7, 2014
P1, N=43, Active, not recruiting, Sponsor: Amgen
N=56 --> 0 N=64 --> 43
- abrilumab (AMG 181) / Amgen, AstraZeneca
Enrollment closed: Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181. (clinicaltrials.gov) - Jan 7, 2014
P1, N=43, Active, not recruiting, Sponsor: Amgen
N=64 --> 43 Recruiting --> Active, not recruiting
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion: Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients (clinicaltrials.gov) - Jan 7, 2014
P1, N=60, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting Terminated --> Completed
- Ibrance (palbociclib) / Pfizer, Kadcyla (ado-trastuzumab emtansine) / Roche
Trial initiation date, Combination therapy, Metastases: Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1) (clinicaltrials.gov) - Jan 6, 2014
P1, N=17, Not yet recruiting, Sponsor: University of Texas Southwestern Medical Center
Terminated --> Completed Initiation date: Oct 2013 --> Jan 2014
- | Neugranin (balugrastim biosimilar) / Teva
Trial initiation date: Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors (clinicaltrials.gov) - Jan 6, 2014
P2, N=36, Not yet recruiting, Sponsor: Teva Pharmaceutical Industries
Initiation date: Oct 2013 --> Jan 2014 Initiation date: Dec 2013 --> Jun 2014
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial initiation date: ProliaHip: Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women (clinicaltrials.gov) - Jan 6, 2014
P4, N=68, Recruiting, Sponsor: Turku University Hospital
Initiation date: Dec 2013 --> Jun 2014 Initiation date: Sep 2013 --> Dec 2013
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Post-transplantation: BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance (clinicaltrials.gov) - Jan 6, 2014
P2, N=6, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Ibrance (palbociclib) / Pfizer
New P1 trial, Combination therapy: Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma (clinicaltrials.gov) - Jan 6, 2014
P1, N=18, Not yet recruiting, Sponsor: Weill Medical College of Cornell University
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: ProliaHip: Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women (clinicaltrials.gov) - Jan 6, 2014
P4, N=68, Recruiting, Sponsor: Turku University Hospital
Initiation date: Sep 2013 --> Dec 2013 Not yet recruiting --> Recruiting
- |||||||||| Ibrance (palbociclib) / Pfizer
New P3 trial: PEARL: Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors (clinicaltrials.gov) - Jan 5, 2014
P3, N=348, Recruiting, Sponsor: Spanish Breast Cancer Research Group
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 5, 2014
P3, N=360, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel) (clinicaltrials.gov) - Jan 5, 2014
P4, N=210, Completed, Sponsor: Amgen
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD)
Enrollment closed: Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies (clinicaltrials.gov) - Jan 2, 2014
P1, N=80, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||||| Repatha (evolocumab) / Amgen, Astellas
Trial completion, Monotherapy: MENDEL-2: Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 (clinicaltrials.gov) - Jan 1, 2014
P3, N=614, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Genasense (oblimersen) / Genta
Trial completion: Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jan 1, 2014
P3, N=0, Completed, Sponsor: Genta Incorporated
Active, not recruiting --> Completed Active, not recruiting --> Completed
- topotecan / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Metastases: Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix (clinicaltrials.gov) - Jan 1, 2014
P2, N=25, Completed, Sponsor: Herbert Irving Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Zarxio (filgrastim-sndz) / Sandoz, Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Enrollment change: Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Dec 29, 2013
P2, N=180, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed N=102 --> 180
- ||| napabucasin (BBI608) / Sumitomo Pharma
New P1 trial, Combination therapy, Metastases: A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - Dec 29, 2013
P1, N=144, Recruiting, Sponsor: Boston Biomedical, Inc
- Enbrel (etanercept) / Pfizer, Amgen
Enrollment change: Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant (clinicaltrials.gov) - Dec 26, 2013
P2, N=34, Completed, Sponsor: University of Michigan Cancer Center
N=102 --> 180 N=25 --> 34
- ||| Procysbi (cysteamine bitartrate delayed release) / Chiesi, Amgen
New P2/3 trial: Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease (clinicaltrials.gov) - Dec 26, 2013
P2/3, N=32, Recruiting, Sponsor: Raptor Pharmaceuticals Inc.
- | Stivarga (regorafenib) / Bayer
New P2 trial, Metastases: Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma (clinicaltrials.gov) - Dec 26, 2013
P2, N=37, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- | Gomekli (mirdametinib) / SpringWorks Therap, Ibrance (palbociclib) / Pfizer
New P1/2 trial: PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors (clinicaltrials.gov) - Dec 26, 2013
P1/2, N=139, Recruiting, Sponsor: Dana-Farber Cancer Institute
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical: Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene (clinicaltrials.gov) - Dec 26, 2013
P1/2, N=35, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=25 --> 34 Not yet recruiting --> Recruiting
- Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant (clinicaltrials.gov) - Dec 26, 2013
P2, N=34, Completed, Sponsor: University of Michigan Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| Evrenzo (roxadustat) / FibroGen
New P3 trial: Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa (clinicaltrials.gov) - Dec 25, 2013
P3, N=570, Recruiting, Sponsor: Astellas Pharma Europe BV
- ||||| Musredo (molidustat) / Bayer
New P2 trial: DIALOGUE 2: Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934 (clinicaltrials.gov) - Dec 25, 2013
P2, N=120, Recruiting, Sponsor: Bayer
- patritumab (U3-1287) / Amgen, Daiichi Sankyo
Trial termination, Metastases: Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Dec 18, 2013
P1, N=12, Terminated, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Recruiting --> Terminated; treatment was not working
- patritumab (U3-1287) / Amgen, Daiichi Sankyo
Enrollment change, Metastases: Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Dec 18, 2013
P1, N=12, Terminated, Sponsor: Washington University School of Medicine
Recruiting --> Terminated; treatment was not working N=25 --> 12
- | Prolia (denosumab) / Amgen
Enrollment change: Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only (clinicaltrials.gov) - Dec 18, 2013
P3, N=35, Completed, Sponsor: Amgen
N=25 --> 12 N=100 --> 35
- |||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New P3 trial, Head-to-Head: A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Dec 18, 2013
P3, N=294, Active, not recruiting, Sponsor: Amgen